Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
about
Active surveillance for prostate cancer: current evidence and contemporary state of practiceUnderstanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancerThe need for a personalized approach for prostate cancer management.The Prostate Health Index: Its Utility in Prostate Cancer DetectionGlycogen synthase kinase-3: a potential preventive target for prostate cancer managementIdentification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach.Standard and Targeted Biopsy During Follow-up for Active Surveillance.KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approachBeyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study.Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.Current Management Strategy for Active Surveillance in Prostate Cancer.Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies.Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance.Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging.In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillanceActive Surveillance of Prostate Cancer.Sociodemographic and Clinical Predictors of Switching to Active Treatment among a Large, Ethnically Diverse Cohort of Men with Low Risk Prostate Cancer on Observational Management.Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer.Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.Expression of the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential.Can nomograms improve our ability to select candidates for active surveillance for prostate cancer?Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance.Predicting clinically significant prostate cancer based on pre-operative patient profile and serum biomarkers.Prostate Cancer Patients' Understanding of the Gleason Scoring System: Implications for Shared Decision-Making.Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients.Biopsy Core Features Are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study.Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era.Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection.Editorial Comment to Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients.Nontoxic Glucomoringin-Isothiocyanate (GMG-ITC) Rich Soluble Extract Induces Apoptosis and Inhibits Proliferation of Human Prostate Adenocarcinoma Cells (PC-3)
P2860
Q28066534-08A75261-C135-473D-A8E2-3C563A49F430Q33591357-B3745003-4062-4E09-B421-540603E9FA81Q33838513-703A21E4-6A19-44C8-A423-57798D930F8FQ35615320-F662E3C4-1AC8-4305-8C02-3D51966F62C5Q35625815-71B8B931-AC04-471E-871C-B6B453C83526Q36328005-24B71E49-3167-44BF-94EB-F702D9E56A72Q36580561-318CD8FB-6B31-4EFE-94D9-6643BAC5EAC5Q38429281-433BC46C-A408-4E2F-85A7-8250602AD40CQ38843915-083BC610-2382-45BE-BFA9-FB11DADA0431Q38849399-604793D9-E041-417B-8C8D-719EFC59CAEFQ38854599-E0644384-354D-4C76-B720-D7C57804E714Q38891544-3D4399C4-9B51-455E-803E-E6A9C6BAE2EFQ38921318-87129A4C-8B57-43E9-9D3E-64496979AA3FQ38930394-4F9C401B-64D0-40F4-AC5A-FD326FB2D74EQ38950908-CA1C548D-55BB-4ED4-93D1-F046D82EECBDQ39356200-A626CDA7-CB8B-4E75-B19E-1B3789716729Q39531223-24F77D14-998C-42FB-9E9D-EAF79EB0A8D3Q40458086-F0F56CC9-6573-4B62-8551-6D39762BE4A5Q40561072-4CEFF0C8-5E28-4811-A8E9-C8B6E846BAE9Q41377631-3C689DA2-471E-41F8-82A0-125AEF3C0829Q41662619-6B36C38E-992D-47A1-AD56-2E8130AB17C5Q41826095-A846C968-4BB6-49A5-BD33-73300E0D10DFQ41829711-AD20D5E9-9CE2-4BA6-BA2D-7B80A818B7DEQ42317551-533527A4-E433-43E2-8B3B-5A5F0319C579Q46883564-2763234A-245F-4771-9F31-1A119BF4B35EQ47153263-EA38E4F5-89BF-4027-89EC-6443634B4463Q47193615-6835DA40-6F99-4189-805A-0122852DEF81Q47732612-21140BCC-52B5-460F-BF92-6317ABA886D2Q48282722-C6AB743B-E5BE-4373-99CB-D2979D728E3BQ48333597-06207432-E436-450C-82F4-1CFFAD098973Q50066944-33FA03E7-13C1-419B-8B0E-82EC782546AEQ52624211-F4D5E52F-52EB-4A1D-B650-894062EB8A7DQ53216904-52404602-5CF3-448B-9C4A-92E0EA02496AQ53425237-40056CCA-111E-4158-BA82-80A88415C1EBQ53852286-89A0EEC8-CEFC-4185-86A4-5BD76B14810FQ57929550-2ED8E762-3E94-4953-B165-650D53CC2FA6
P2860
Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Active surveillance for prosta ...... rkers for risk stratification.
@ast
Active surveillance for prosta ...... rkers for risk stratification.
@en
type
label
Active surveillance for prosta ...... rkers for risk stratification.
@ast
Active surveillance for prosta ...... rkers for risk stratification.
@en
prefLabel
Active surveillance for prosta ...... rkers for risk stratification.
@ast
Active surveillance for prosta ...... rkers for risk stratification.
@en
P2093
P2860
P50
P1433
P1476
Active surveillance for prosta ...... arkers for risk stratification
@en
P2093
Alberto Briganti
Sigrid V Carlsson
Sophie M Bruinsma
Tom Pickles
Yoshiyuki Kakehi
P2860
P304
P356
10.1016/J.EURURO.2014.10.010
P407
P577
2014-10-31T00:00:00Z